Lifestyle Let's talk stocks!

Welcome to our Community
Wanting to join the rest of our members? Feel free to Sign Up today.
Sign up

jasonhightower

"You're not even training are you Frenchy?"
Jan 2, 2017
1,115
1,686
I'm formulating something for weed stocks. My value investing doesn't work well with them because the financials are all over the place, usually. I'll be paper trading a couple that has popped up on my screener that look promising to see if I can pick these somewhat consistently.
I'm interested in what you find, as I'd like to diversify a bit in the weed stocks. I've generally looked for those with specific patents or licensing along with companies who have multi-use (somewhat like sector diversification, if that's a word).

I've got these currently:
TWMJF - Canopy Growth Corporation
GBLX - Growblox Sciences
 

b00ts

pews&vrooms
Amateur Fighter
Oct 21, 2015
5,599
8,635
I'm interested in what you find, as I'd like to diversify a bit in the weed stocks. I've generally looked for those with specific patents or licensing along with companies who have multi-use (somewhat like sector diversification, if that's a word).

I've got these currently:
TWMJF - Canopy Growth Corporation
GBLX - Growblox Sciences
GBLX is going to be coming back down, I believe. Momentum indicators show it and it didn't touch the two-year resistance of $.65 I could also be completely fucking wrong.
 

jasonhightower

"You're not even training are you Frenchy?"
Jan 2, 2017
1,115
1,686
GBLX is going to be coming back down, I believe. Momentum indicators show it and it didn't touch the two-year resistance of $.65 I could also be completely fucking wrong.
I agree with you, we saw it yesterday and today. I'll probably grab more at the low levels with intent on going long.
 

b00ts

pews&vrooms
Amateur Fighter
Oct 21, 2015
5,599
8,635
I'm getting clobbered again today :mad:
Got my signals for AOBC and bought in at $19.39. User Lindsay on the OG opened my eyes to price and volume analysis, so I'm going to be studying that for a few weeks to try and get these penny stocks down.
 

Hauler

Been fallin so long it's like gravitys gone
Feb 3, 2016
45,561
57,916
Got my signals for AOBC and bought in at $19.39. User Lindsay on the OG opened my eyes to price and volume analysis, so I'm going to be studying that for a few weeks to try and get these penny stocks down.
I need to come up with a system. I do OK, but I'm mostly just winging it.
 

b00ts

pews&vrooms
Amateur Fighter
Oct 21, 2015
5,599
8,635
I need to come up with a system. I do OK, but I'm mostly just winging it.
I'm ok at finding value and making a swing trade off of it. Some of those can take months or years to reach their true value and you may need to get in and out a few times. I'm lost with the volatile penny stocks though. It's straight technical analysis. I want in on that high of buying less than a penny and selling at a dollar based purely off a swing high. It's like gambling without having to drive to a casino and wait on the beer cart.
 

b00ts

pews&vrooms
Amateur Fighter
Oct 21, 2015
5,599
8,635
I will quote what I wrote on one of the OG stock threads for how I figure value. I consider myself a value investor, but I'm torn because I want to learn technical analysis for penny stocks. Value investing is all about patience. Penny stock is all about playing the charts.

For the little bit of technical analysis I use along with the following method, I use Prophet in TD Ameritrade's thinkorswim. I go to studies and get a 10-period MA w/ breakout, 8-17-9 MACD histogram w/breakout, stochastic 14-5 w/ breakout. I watch daily charts and buy with the three breakouts line up within a day of each other. Sell when the red ones do the same. You can sell early if you feel the momentum is changing. I've also started using Heikin Ashi candles to find trend reversals.

Note that I've read a few value investing books and they all somewhat mimic the same method. Just different authors. I suggest Ben Graham's book for a good look at value investing.

And to add....you also have to make sure that the CEO has the shareholders in mind, the business or product has a "moat"(meaning it can withstand competition), and the business has meaning.

So...first thing I want to do, when I see a company that I like and know the product, is to check the financials. I'm looking for growth of around 10% over 10-years, to get a true value.



Let's take AOBC:

ROIC - 9% -- not where I'd like, but workable.

BVPS - 12% -- Equity growth over 10-years

EPS - 18% -- Earings/share growth over 10-years

Sales - 12% -- Revenue growth over 10-years

OCF - 27% -- Operating cash flow growth for 10-years



Looking at my equity growth over a 10-year period, I would say the company can have a future growth of about 12%. I check with what the analyst thinks it's 15%. I'm going with my conservative 12% estimate.


I get my TTM EPS, my estimated OR analyst growth rate(whichever is the lower number), and a rough estimate for future P/E... which is roughly two times the growth rate.

2.36 - TTM EPS according to Morningstar

12% - 10-year estimated growth rate

24 - estimate P/E

We also want a rate of return of 15% per year.



I grow my EPS for 10 years -- 2.36 * (1.12^10) = 7.34 **Rounded**

I get my multiple, my P/E -- 12 * 2 = 24

I get my future stock price -- 7.34 * 24 = $176.16 (lol right)



The stock price, with the current growth, SHOULD be at $176.16 in 10-years

The get a 15% rate of return per year, I need to see what the value SHOULD BE TODAY.

We take 1/4 of the 10-year price... $44.04. Our current value should be $44.04, but we don't want to pay full price. We take a queue from Ben Graham and buy at 1/3 that price or our margin of safety. That will be $29.51.



I then use a couple indicators to know when to buy in, get in and out with market makers when the indicators give me signals, and ride the waves until I get to or above the value of $44. This may be a few months on some stocks or years on others, such as AOBC. Look at the 20y chart, the price is correcting itself slowly with the growth of the company. I'm buying at a discount and watching for the market to correct itself.

Once the value or above is reached or the signals put me out early, it just goes on the watch list to wait for another opportunity to buy.
 

La Paix

Fuck this place
First 100
Jan 14, 2015
38,273
64,597
Check out Lexaria - LXRP

Buy Hemp Seed Oil Products, Tea Bags | Hemp Tea Benefits Health

Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. Cannabinoids are poorly absorbed by the body’s gastrointestinal tract and consumers often default to alternate routes of administration like smoking to achieve higher effectiveness





I know very little about the market but we have shares with them and it's been rewarding.
Lexaria Receives Notice of its First Patent to be Granted in Australia for Cannabinoid Infused Edibles


 
Last edited:

b00ts

pews&vrooms
Amateur Fighter
Oct 21, 2015
5,599
8,635
Hauler @Alco Hauler Pretty much what I was trying to tell you about AOBC, but I suck in explaining the why I analyze.

Summary
Strategy shift to focus on expanding into non-cyclical markets.

Management is making wise capital allocation decisions with high ROIC.

Based on ROIIC and capital reinvestment rates, AOBC is growing the intrinsic value of the business by 24% annually.

Overview

American Outdoor Brands, Corp. (NASDAQ:AOBC), formerly Smith & Wesson Holding Corp. (SWHC), is a holding company that markets firearms and outdoor sporting goods under various brands such as the Smith & Wesson, Crimson Trace, and Battenfeld Technologies, among others. The company's history stretches back over 160 years where they got their start manufacturing firearms under the Smith & Wesson brand. For those that are unfamiliar with the Smith & Wesson brand, I would consider it the Nike or Coca-Cola of the firearms industry where one out of every two revolvers in the U.S. today is a Smith & Wesson. Many Americans are familiar with the S&W brand through ownership of a firearm, association with S&W owners, or S&W media exposure in such movies as "Dirty Harry." Today, the S&W brand is housed under the AOBC umbrella, is the one of the leading manufacturers, marketers, and exporters of firearms in the U.S.

Strategy Shift & Growth

So you may be wondering, "If Smith & Wesson is so popular, why did they change their name from Smith & Wesson Holding Corp. to American Outdoor Brands Corp.?" Firearms are an extremely cyclical business. While there does exist a segment of the population that collects newly released models of firearms, much like Nike's Jordan fanatics, consumer firearm sales tend to follow volatile political and economic patterns. Sales tend to increase dramatically when the public fears increased gun regulation or the economy is in a down cycle and people feel the need to product their homes/assets. Due to the cycle nature of the firearm industry, management made the decision to expand into parallel but correlated niche markets of the outdoor sporting goods industry to make the business less cyclical for shareholders. As of January 2016, AOBC operates much like Berkshire Hathaway or Johnson & Johnson where it is nothing more than a holding company of excellent brands.


The decision to alter strategies was made by what I consider to be prudent and owner-minded management. In 2011 (AOBC's FY2012), James Debney was promoted to CEO of AOBC. Debney was the president of National Presto (NYSE:NPK) from 2006-2009 and if you take a look at their financial statements, they have not seen the same revenue, earnings, or margin growth since he left. AOBC has seen significant growth and improvements in revenue, earnings, margins, etc. since he became CEO in 2011:

  • Revenue (2011-2016): 16% CAGR
  • Operating Cash Flow: 34%
  • Free Cash Flow: 51%
  • Net Income: 56%
  • Book Value: 22%
  • Shares Outstanding: -2.6%
  • Gross Margin: 30.6% to 40.6%
  • Operating Margin: 5.2% to 21.9%
AOBC grew firearm revenue from $328M to $600M from 2011 to 2016. However, the percentage of total revenue contributed by firearm sales dropped from 96% in 2011 to 83% in 2016. The other 17% came from strategic acquisitions into the firearm accessories and outdoor sporting goods markets.

Management

Warren Buffett & Charlie Munger have always held the belief that corporate management, especially the CEO, should first and foremost be an excellent allocator of capital. More often than not, when companies start depending on acquisitions for growth they make poor capital allocation decisions, acquiring at premiums and leveraging up the balance sheet. In the FY2014 Annual Report under Strategy, management states that they are "focused on growth but only in areas that provide accepted return on invested capital." This statement had not been present in the five prior annual reports and after reading through the reports, it became evident to me that AOBC's management have been wisely allocating capital to grow the business and benefit shareholders. Here are examples since the CEO change:

  • AOBC held the rights to produce and market Walther Firearms, maker of the famous PPK, products in the U.S. from 2002 to 2014. They ended the partnership because the manufacturing of lower margin Walther products was not as profitable as higher margin S&W products.
  • Prior management acquired Universal Safety Products (renamed to Smith & Wesson Security Solutions), a perimeter security company, in 2009. Management discontinued and divested this business in 2012 due margin compression and lower revenue from constrained government budgets.
  • Management acquired Battenfeld Technologies (NYSEMKT:BTI) in December of 2014 (FY2015) for $135.4M. Battenfeld had been growing revenues at 22% annually since 2008 and contributed $20.6M to AOBC's top line in FY2015. Due to being acquired with only 4 months left in the year, that equates to an adjusted premium of 2.2x sales, or 45% return on investment.
  • DRP was acquired at the beginning of FY2015 for $23.8M and contributed $10.6M to revenue; another acquisition for 2.2x sales and 45% return on investment.
  • In the fall of 2016 (FY2017), AOBC acquired Crimson Trace and Universal Survival Technologies (UST). Crimson Trace and UST had been growing revenues, compounded annually, at 10% and 49%, respectfully. FY2017 will be reported in June so the numbers are not available for these acquisitions yet. Based on this management's recent track record, I am confident that these were smart buys.

All of these acquisitions have been made with cash on-hand, current cash flow, and minimum debt. If debt was issued, the purchase price was low enough and cash flow strong enough that the acquisition was paid for within 12-18 months. Also, due to the structure of the holding company, AOBC is vertically integrating what they call the "distracting" parts of these companies, such as HR, Finance, etc. and retaining executive leadership, sales, marketing, and R&D.

Furthermore, management started a repurchase program and purchased $165M in shares between April 2012 and April 2015. These purchases were made in FY2013 & FY2014:

  • 2.1M shares @ $9.53: P/E 8.1
  • 7.5M shares @ $10.00: P/E 8.5
  • 10.1M shares @ $11.32: P/E 7.6
They authorized another $50M for repurchases in June 2015 that expires in June 2017 but have not made any repurchases yet. The PE between June 2015 and Q4 2016 averaged above 15. Debney, personally, has recently been on a shopping spree buying shares. I am fairly certain that if management has been this prudent and insiders are buying, they are unloading that $50M right now to repurchase a little over 4% of shares outstanding.

Concerns

The biggest concern for shareholders at the moment is the forecasted decrease in NICS background checks and softer firearms market due to the recent election and alleviating fears of heightened gun control by this administration. While this may be true in the short term, over the past 10 years, NICS background checks have grown at 7.5% annually. For short-term, swing trade investors, this is not what you want to hear and may be why 25% of the shares outstanding are being shorted. An opportunity may have presented itself for the 2-5+ year investors who are armed with the knowledge that the firearms market in the U.S. and NICS checks continue to grow at 4.6% and 7.5% annually, respectfully. This and management's efforts to diversify revenue to non-cyclical businesses presents an opportunity.




A second concern is management not making good capital allocation decisions moving forward. Based on their prior track record, I believe that they are a good bet although I will continue to monitor this closely.

Valuation

Qualitatively, I really like what I am seeing with top/bottom line growth and managements efforts to allocate capital effectively. Quantitatively, I need to figure out what the business is intrinsically worth based on a desired rate of return (or discount rate). When I evaluate intrinsic value and the growth of that value within a company, I like to look at Return on Incremental Invested Capital (ROIIC). There is a great article by John Huber at Base Hitting on the background and specifics of ROIIC. In essence, I want to quantitatively understand how effectively management has been allocating capital and what percentage of capital is being allocated over a certain time frame in order to forecast capital allocation returns in the future. I use the below calculations:

  • ROIIC: Change in earnings (or cash flow) / Change in capital invested; i.e. ROIIC = $78M ($131M) / $243M = 32.1% (53.9%)
  • Reinvestment Rate: Capital Invested / Cumulative Earnings or Cash Flow; i.e. Reinvesment Rate = $243M / $328M ($510M) = 74% (47.6%)
  • Intrinsic Growth: ROIIC x Reinvestment Rate; i.e. Intrinsic Growth = 32.1% (53.9%) x 74% (47.6%) = 23.7% (25.7%)
After comparing total capital invested and the reinvestment rate of that capital to the change in net income and operating cash flow, I calculated that the intrinsic value of the business has been growing at ~24% annually since 2012 (Debney's first full FY). This correlates closely with the 22% CAGR of book value and 27% RoRE (incorporates ~3% decline in outstanding shares).

If I apply a 20% growth rate (4% less than the 24% calculated) to Net Income & OCF and reduce outstanding shares by 3% annually, here is what I expect the business to be producing in 2022:

  • Net Income: $94M (2016) to $234M (2022)
  • OCF: $169M to $420M Shares Outstanding: 56M to 48M
I believe that AOBC could and should be trading at valuation multiples of 10x P/E and 6x P/CF, which is close to long term averages. This gives me a future price in 2022 between $48-$52/share, or a CAGR of 20%-22% from today's price of $19.50/share. Of course the growth rate or multiples could be lower moving forward but I expect that as AOBC continues to grow its core business, expand margins and revenue by acquiring strategic, higher margin business, and reducing share count when prices are attractive, we will see intrinsic growth rates similar to what we have seen in the past.

Conclusion

I believe that while the S&W brand is the beginning of a moat in itself for AOBC, the cyclical and discretionary nature of firearms does not allow this moat to grow unassisted. AOBC's management has shown in recent years that they are allocating capital wisely and getting good returns on said invested capital. If management continues to expand wisely into new growth markets while growing margins and revenue in firearms, we should see 15% CAGR at a minimum for the next 5 years.

Disclosure: I am/we are long AOBC.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
 
Last edited:

Hauler

Been fallin so long it's like gravitys gone
Feb 3, 2016
45,561
57,916
Hauler @Alco Hauler Pretty much what I was trying to tell you about AOBC, but I suck in explaining the why I analyze.

Summary
Strategy shift to focus on expanding into non-cyclical markets.

Management is making wise capital allocation decisions with high ROIC.

Based on ROIIC and capital reinvestment rates, AOBC is growing the intrinsic value of the business by 24% annually.

Overview

American Outdoor Brands, Corp. (NASDAQ:AOBC), formerly Smith & Wesson Holding Corp. (SWHC), is a holding company that markets firearms and outdoor sporting goods under various brands such as the Smith & Wesson, Crimson Trace, and Battenfeld Technologies, among others. The company's history stretches back over 160 years where they got their start manufacturing firearms under the Smith & Wesson brand. For those that are unfamiliar with the Smith & Wesson brand, I would consider it the Nike or Coca-Cola of the firearms industry where one out of every two revolvers in the U.S. today is a Smith & Wesson. Many Americans are familiar with the S&W brand through ownership of a firearm, association with S&W owners, or S&W media exposure in such movies as "Dirty Harry." Today, the S&W brand is housed under the AOBC umbrella, is the one of the leading manufacturers, marketers, and exporters of firearms in the U.S.

Strategy Shift & Growth

So you may be wondering, "If Smith & Wesson is so popular, why did they change their name from Smith & Wesson Holding Corp. to American Outdoor Brands Corp.?" Firearms are an extremely cyclical business. While there does exist a segment of the population that collects newly released models of firearms, much like Nike's Jordan fanatics, consumer firearm sales tend to follow volatile political and economic patterns. Sales tend to increase dramatically when the public fears increased gun regulation or the economy is in a down cycle and people feel the need to product their homes/assets. Due to the cycle nature of the firearm industry, management made the decision to expand into parallel but correlated niche markets of the outdoor sporting goods industry to make the business less cyclical for shareholders. As of January 2016, AOBC operates much like Berkshire Hathaway or Johnson & Johnson where it is nothing more than a holding company of excellent brands.


The decision to alter strategies was made by what I consider to be prudent and owner-minded management. In 2011 (AOBC's FY2012), James Debney was promoted to CEO of AOBC. Debney was the president of National Presto (NYSE:NPK) from 2006-2009 and if you take a look at their financial statements, they have not seen the same revenue, earnings, or margin growth since he left. AOBC has seen significant growth and improvements in revenue, earnings, margins, etc. since he became CEO in 2011:

  • Revenue (2011-2016): 16% CAGR
  • Operating Cash Flow: 34%
  • Free Cash Flow: 51%
  • Net Income: 56%
  • Book Value: 22%
  • Shares Outstanding: -2.6%
  • Gross Margin: 30.6% to 40.6%
  • Operating Margin: 5.2% to 21.9%
AOBC grew firearm revenue from $328M to $600M from 2011 to 2016. However, the percentage of total revenue contributed by firearm sales dropped from 96% in 2011 to 83% in 2016. The other 17% came from strategic acquisitions into the firearm accessories and outdoor sporting goods markets.

Management

Warren Buffett & Charlie Munger have always held the belief that corporate management, especially the CEO, should first and foremost be an excellent allocator of capital. More often than not, when companies start depending on acquisitions for growth they make poor capital allocation decisions, acquiring at premiums and leveraging up the balance sheet. In the FY2014 Annual Report under Strategy, management states that they are "focused on growth but only in areas that provide accepted return on invested capital." This statement had not been present in the five prior annual reports and after reading through the reports, it became evident to me that AOBC's management have been wisely allocating capital to grow the business and benefit shareholders. Here are examples since the CEO change:

  • AOBC held the rights to produce and market Walther Firearms, maker of the famous PPK, products in the U.S. from 2002 to 2014. They ended the partnership because the manufacturing of lower margin Walther products was not as profitable as higher margin S&W products.
  • Prior management acquired Universal Safety Products (renamed to Smith & Wesson Security Solutions), a perimeter security company, in 2009. Management discontinued and divested this business in 2012 due margin compression and lower revenue from constrained government budgets.
  • Management acquired Battenfeld Technologies (NYSEMKT:BTI) in December of 2014 (FY2015) for $135.4M. Battenfeld had been growing revenues at 22% annually since 2008 and contributed $20.6M to AOBC's top line in FY2015. Due to being acquired with only 4 months left in the year, that equates to an adjusted premium of 2.2x sales, or 45% return on investment.
  • DRP was acquired at the beginning of FY2015 for $23.8M and contributed $10.6M to revenue; another acquisition for 2.2x sales and 45% return on investment.
  • In the fall of 2016 (FY2017), AOBC acquired Crimson Trace and Universal Survival Technologies (UST). Crimson Trace and UST had been growing revenues, compounded annually, at 10% and 49%, respectfully. FY2017 will be reported in June so the numbers are not available for these acquisitions yet. Based on this management's recent track record, I am confident that these were smart buys.

All of these acquisitions have been made with cash on-hand, current cash flow, and minimum debt. If debt was issued, the purchase price was low enough and cash flow strong enough that the acquisition was paid for within 12-18 months. Also, due to the structure of the holding company, AOBC is vertically integrating what they call the "distracting" parts of these companies, such as HR, Finance, etc. and retaining executive leadership, sales, marketing, and R&D.

Furthermore, management started a repurchase program and purchased $165M in shares between April 2012 and April 2015. These purchases were made in FY2013 & FY2014:

  • 2.1M shares @ $9.53: P/E 8.1
  • 7.5M shares @ $10.00: P/E 8.5
  • 10.1M shares @ $11.32: P/E 7.6
They authorized another $50M for repurchases in June 2015 that expires in June 2017 but have not made any repurchases yet. The PE between June 2015 and Q4 2016 averaged above 15. Debney, personally, has recently been on a shopping spree buying shares. I am fairly certain that if management has been this prudent and insiders are buying, they are unloading that $50M right now to repurchase a little over 4% of shares outstanding.

Concerns

The biggest concern for shareholders at the moment is the forecasted decrease in NICS background checks and softer firearms market due to the recent election and alleviating fears of heightened gun control by this administration. While this may be true in the short term, over the past 10 years, NICS background checks have grown at 7.5% annually. For short-term, swing trade investors, this is not what you want to hear and may be why 25% of the shares outstanding are being shorted. An opportunity may have presented itself for the 2-5+ year investors who are armed with the knowledge that the firearms market in the U.S. and NICS checks continue to grow at 4.6% and 7.5% annually, respectfully. This and management's efforts to diversify revenue to non-cyclical businesses presents an opportunity.




A second concern is management not making good capital allocation decisions moving forward. Based on their prior track record, I believe that they are a good bet although I will continue to monitor this closely.

Valuation

Qualitatively, I really like what I am seeing with top/bottom line growth and managements efforts to allocate capital effectively. Quantitatively, I need to figure out what the business is intrinsically worth based on a desired rate of return (or discount rate). When I evaluate intrinsic value and the growth of that value within a company, I like to look at Return on Incremental Invested Capital (ROIIC). There is a great article by John Huber at Base Hitting on the background and specifics of ROIIC. In essence, I want to quantitatively understand how effectively management has been allocating capital and what percentage of capital is being allocated over a certain time frame in order to forecast capital allocation returns in the future. I use the below calculations:

  • ROIIC: Change in earnings (or cash flow) / Change in capital invested; i.e. ROIIC = $78M ($131M) / $243M = 32.1% (53.9%)
  • Reinvestment Rate: Capital Invested / Cumulative Earnings or Cash Flow; i.e. Reinvesment Rate = $243M / $328M ($510M) = 74% (47.6%)
  • Intrinsic Growth: ROIIC x Reinvestment Rate; i.e. Intrinsic Growth = 32.1% (53.9%) x 74% (47.6%) = 23.7% (25.7%)
After comparing total capital invested and the reinvestment rate of that capital to the change in net income and operating cash flow, I calculated that the intrinsic value of the business has been growing at ~24% annually since 2012 (Debney's first full FY). This correlates closely with the 22% CAGR of book value and 27% RoRE (incorporates ~3% decline in outstanding shares).




If I apply a 20% growth rate (4% less than the 24% calculated) to Net Income & OCF and reduce outstanding shares by 3% annually, here is what I expect the business to be producing in 2022:

  • Net Income: $94M (2016) to $234M (2022)
  • OCF: $169M to $420M Shares Outstanding: 56M to 48M
I believe that AOBC could and should be trading at valuation multiples of 10x P/E and 6x P/CF, which is close to long term averages. This gives me a future price in 2022 between $48-$52/share, or a CAGR of 20%-22% from today's price of $19.50/share. Of course the growth rate or multiples could be lower moving forward but I expect that as AOBC continues to grow its core business, expand margins and revenue by acquiring strategic, higher margin business, and reducing share count when prices are attractive, we will see intrinsic growth rates similar to what we have seen in the past.

Conclusion

I believe that while the S&W brand is the beginning of a moat in itself for AOBC, the cyclical and discretionary nature of firearms does not allow this moat to grow unassisted. AOBC's management has shown in recent years that they are allocating capital wisely and getting good returns on said invested capital. If management continues to expand wisely into new growth markets while growing margins and revenue in firearms, we should see 15% CAGR at a minimum for the next 5 years.

Disclosure: I am/we are long AOBC.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Good info. Thanks. Makes me feel better about already buying in. :)
 

b00ts

pews&vrooms
Amateur Fighter
Oct 21, 2015
5,599
8,635
$PDLI popped up on the Small Cap Penny scan and is going on my watch list. Just announced repurchase of $30 million common stock through 2018. CEO seems to be looking out for shareholders. Good numbers the last 5yrs. Do your own DD. Put the MoS price at roughly $1.80...it's $2.12 at last close.

 

jasonhightower

"You're not even training are you Frenchy?"
Jan 2, 2017
1,115
1,686
$PDLI popped up on the Small Cap Penny scan and is going on my watch list. Just announced repurchase of $30 million common stock through 2018. CEO seems to be looking out for shareholders. Good numbers the last 5yrs. Do your own DD. Put the MoS price at roughly $1.80...it's $2.12 at last close.

Down to $2.05 today. Any idea why they've lost 32% over the past year?
 

b00ts

pews&vrooms
Amateur Fighter
Oct 21, 2015
5,599
8,635
Down to $2.05 today. Any idea why they've lost 32% over the past year?
They had a patent expire in the beginning of 2016 and only recently picked up a new investment in a company called Noden... I expect this to go to at least $1.20.

"DUBLIN, IRELAND, July 6, 2016 – Noden Pharma DAC is pleased to announce that today it has closed the transaction relating to a purchase agreement with Novartis AG (Novartis), entered into on May 24, 2016, to acquire exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world. The product’s active ingredient is aliskiren, which is indicated for the treatment of hypertension. The drug was previously marketed by Novartis and had global sales in 2015 of $154 million. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act applicable to the acquisition has been terminated by the United States Federal Trade Commission fulfilling the last remaining condition to close the transaction.

“It is with great pleasure that we announce this product acquisition from Novartis,. The unique mode of action and product profile of Tekturna provides a compelling alternative for physicians in the hypertension category. This acquisition brings immediate critical mass and its global product footprint allows for future product acquisition opportunities to be pursued across key geographic markets,” said Elie Farah, President and CEO of Noden Pharma DAC.

Noden has funded the transaction with a combination of debt and funds provided via equity issuances. PDL BioPharma Inc. (PDL) expects to make equity contributions to Noden Pharma DAC, a privately held company, totaling approximately $107 million in the first year of the transaction, with an initial equity investment of $75 million which has been made upon closing of the transaction, and an additional $32 million equity contribution commitment on the one-year anniversary of the closing of the transaction. PDL’s equity investment will ultimately result in an 88% equity interest in Noden.

“Since 2013, PDL has placed approximately $1 billion of capital in healthcare income generating assets led by their President and CEO, Mr. John McLaughlin. I am confident that PDL will be an excellent partner based on their stellar track record and my prior financing experience with PDL while I was CEO of another specialty pharma company. I look forward to working with Mr. McLaughlin and the PDL team as we build Noden going forward,” stated Elie Farah. Bloom Burton and Co. acted as financial advisor to Noden on the transaction.

About Tekturna

Tekturna, also known as Rasilez outside the U.S., is a high blood pressure medication. It is the only product available in a class of high blood pressure drugs called "direct renin inhibitors," which lowers blood pressure by blocking the enzyme renin."
 

jasonhightower

"You're not even training are you Frenchy?"
Jan 2, 2017
1,115
1,686
They had a patent expire in the beginning of 2016 and only recently picked up a new investment in a company called Noden... I expect this to go to at least $1.20.

"DUBLIN, IRELAND, July 6, 2016 – Noden Pharma DAC is pleased to announce that today it has closed the transaction relating to a purchase agreement with Novartis AG (Novartis), entered into on May 24, 2016, to acquire exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world. The product’s active ingredient is aliskiren, which is indicated for the treatment of hypertension. The drug was previously marketed by Novartis and had global sales in 2015 of $154 million. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act applicable to the acquisition has been terminated by the United States Federal Trade Commission fulfilling the last remaining condition to close the transaction.

“It is with great pleasure that we announce this product acquisition from Novartis,. The unique mode of action and product profile of Tekturna provides a compelling alternative for physicians in the hypertension category. This acquisition brings immediate critical mass and its global product footprint allows for future product acquisition opportunities to be pursued across key geographic markets,” said Elie Farah, President and CEO of Noden Pharma DAC.

Noden has funded the transaction with a combination of debt and funds provided via equity issuances. PDL BioPharma Inc. (PDL) expects to make equity contributions to Noden Pharma DAC, a privately held company, totaling approximately $107 million in the first year of the transaction, with an initial equity investment of $75 million which has been made upon closing of the transaction, and an additional $32 million equity contribution commitment on the one-year anniversary of the closing of the transaction. PDL’s equity investment will ultimately result in an 88% equity interest in Noden.

“Since 2013, PDL has placed approximately $1 billion of capital in healthcare income generating assets led by their President and CEO, Mr. John McLaughlin. I am confident that PDL will be an excellent partner based on their stellar track record and my prior financing experience with PDL while I was CEO of another specialty pharma company. I look forward to working with Mr. McLaughlin and the PDL team as we build Noden going forward,” stated Elie Farah. Bloom Burton and Co. acted as financial advisor to Noden on the transaction.

About Tekturna

Tekturna, also known as Rasilez outside the U.S., is a high blood pressure medication. It is the only product available in a class of high blood pressure drugs called "direct renin inhibitors," which lowers blood pressure by blocking the enzyme renin."
Very nice. It's on my watchlist now too. Thanks for sharing this one.
 

b00ts

pews&vrooms
Amateur Fighter
Oct 21, 2015
5,599
8,635
Very nice. It's on my watchlist now too. Thanks for sharing this one.
Reading over the earnings call transcript for Q4 2016 that was released yesterday. They acknowledge their shortcomings and how they plan to go forward... good things when looking at management. They also have cash and expect a 44% cash increase in this quarter.

You can listen here, if interested, or view the slideshow...whenever I find the bitch.

***Edit- Found it attached to the bottom of the 8-K filed yesterday
PDL BioPharma, Inc. 8-K Mar. 1, 2017 4:09 PM | Seeking Alpha
 

Wild

Zi Nazi
Admin
Dec 31, 2014
85,153
123,522
This bull market can't continue right? Talking to our company financial guy, he said a 15% to 20% pullback is likely imminent.

I'm sitting it out until this occurs because I think it's very likely as well. When it happens, I'll jump in balls deep.
 

b00ts

pews&vrooms
Amateur Fighter
Oct 21, 2015
5,599
8,635
This bull market can't continue right? Talking to our company financial guy, he said a 15% to 20% pullback is likely imminent.

I'm sitting it out until this occurs because I think it's very likely as well. When it happens, I'll jump in balls deep.
My camp of investing will love it. So many good companies will be on sale.
 

Hauler

Been fallin so long it's like gravitys gone
Feb 3, 2016
45,561
57,916
This bull market can't continue right? Talking to our company financial guy, he said a 15% to 20% pullback is likely imminent.

I'm sitting it out until this occurs because I think it's very likely as well. When it happens, I'll jump in balls deep.
It has to correct itself eventually.
 

jasonhightower

"You're not even training are you Frenchy?"
Jan 2, 2017
1,115
1,686
This bull market can't continue right? Talking to our company financial guy, he said a 15% to 20% pullback is likely imminent.

I'm sitting it out until this occurs because I think it's very likely as well. When it happens, I'll jump in balls deep.
I've been thinking of getting prepared for that.
 

jasonhightower

"You're not even training are you Frenchy?"
Jan 2, 2017
1,115
1,686
Got my signals for AOBC and bought in at $19.39. User Lindsay on the OG opened my eyes to price and volume analysis, so I'm going to be studying that for a few weeks to try and get these penny stocks down.
AOBC getting hit in early trading. I'm gonna get in now I think. Looks like some initial reaction to price target cuts coming out yesterday.

Crazy because it seems to still have a bullish outlook with price targets in the low to mid twenties. Trading at $17.64 now.
 

b00ts

pews&vrooms
Amateur Fighter
Oct 21, 2015
5,599
8,635
Hauler @Alco Hauler What's fracking looking like? Was thinking about hitting the numbers on a few companies this weekend to try and find a gem that the market has undervalued. I think a good play would be for service companies, instead of the big name drillers... think proppant, water treatment, etc.